Licorice root (Glycyrrhiza glabra) trials recruiting now
2 registrations that name licorice root as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT06798948
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Phase 2
Li Lab,MD
About 100 people
Started Mar 1, 2025
In plain words A Phase 2 study of licorice root in people 18 to 65, run by Li Lab,MD. It plans to enroll about 100 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Metabolic-associated Fatty Liver Disease (MAFLD).
Subjects who meet the clinical diagnostic criteria for metabolic-associated fatty liver disease and have mild to moderate fatty liver.
Aged 18-65, regardless of gender.
Have not taken any liver-protecting medications in the past 3 months.
Informed subjects who voluntarily sign the informed consent form and agree to participate in all visits and treatments as required by the trial protocol.
The exclusion criteria are on the listing.
What it tests, as registered
Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra; Placebo maltodextrin
Registered summary
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals. With the prevalence of obesity and type 2 diabetes, the morbidity and incidence of MAFLD have been increasing globally, particularly in China. MAFLD and metabolic syndrome as well as type 2 diabetes are mutually causal, jointly promoting the incidence of atherosclerotic cardiovascular disease, chronic kidney disease, liver decompensation, and malignant tumors such as hepatocellular carcinoma. The full summary is on the listing.
Where, as registered
No US site; China (2).
Not yet recruitingNCT06269406
A Combination of Ibuprofen With Curcumin Covered With Liquorice Root Supplementation in the Management of Postoperative Dental Pain in Adults
No phase
S.LAB (SOLOWAYS)
About 264 people
Starts Jul 28, 2025 (estimated)
In plain words A study of licorice root in people 18 to 85, run by S.LAB (SOLOWAYS). It plans to enroll about 264 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 85. Conditions: Dental Pain.
Removal of 2 to 4 impacted third molars
The exclusion criteria are on the listing.
What it tests, as registered
ibuprofen 400 mg in combination with Curcumin covered with liquorice root 100 mg; ibuprofen 200 mg in combination with Curcumin covered with liquorice root 100 mg; The combination of ibuprofen 400 mg and placebo in patients after 2-4 molars procedure
Registered summary
Dental pain, a common issue in stomatology, requires a multifaceted treatment approach. This study explores the efficacy of combining Ibuprofen with curcumin and liquorice root supplements for managing postoperative dental pain. Curcumin, known for its antioxidant and anti-inflammatory properties, along with liquorice root, may enhance pain relief beyond conventional NSAIDs like Ibuprofen. This randomized, double-blind, placebo-controlled trial aims to evaluate the safety and effectiveness of this combination therapy in adults undergoing the removal of impacted third molars. The full summary is on the listing.